COVID-19

ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients with COVID-19 (Adapt Out COVID)

Post Date: 
2021-07-21
   |   
Countries: 
India
United States
   |   
Clinical Sites: 
BJGMC
Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease progression, and reduce serious complications of COVID-19 and transmission [10]. ACTIV-2/A5401 is a phase II/III randomized, blinded, controlled adaptive platform trial to...

Project COVID-19 Test At Home

Post Date: 
2021-06-28
   |   
Countries: 
United States
This study to test the accuracy of a COVID-19 test for use at home. This test has been authorized by the FDA to be done in a health care setting by a health care provider, but the study is evaluating diagnostic accuracy of tests administered at home

COVID-19 Viral Dynamics

Post Date: 
2020-12-20
   |   
Countries: 
United States
Purpose of the study: This study aims to quantitatively define the relationships between (a) testing results obtained via multiple distinct platforms (antigen vs. RT-qPCR), (b) shedding of infectious virus, and (c) self-reported disease symptoms over the course of SARS-CoV-2 infection.

RADx Tech COVID-19 Test US Study

Post Date: 
2020-08-05
   |   
Countries: 
United States
Rationale: Scalable, inexpensive point-of-care (PoC) technologies that enable detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus are desperately needed. However, understanding the accuracy and usability of novel PoC technologies for SARS-CoV-2 is critical. Each PoC...

RADx Tech COVID-19 Test Us Bank

Post Date: 
2020-08-05
   |   
Countries: 
United States
This study is collecting and storing lab samples of COVID-19 diagnostic tests among both people who have tested positive for COVID and those who haven’t to evaluate new COVID test and study how COVID-19 and related viruses cause disease in people.

RADx Tech COVID-19 Test Us Study

Post Date: 
2020-07-27
   |   
Countries: 
United States
Scalable, inexpensive novel technologies that enable detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus are desperately needed. However, understanding the accuracy and usability of novel technologies for SARS-CoV-2 is critical. Each novel test needs to be evaluated...

Epidemiology and Clinical Outcomes of COVID-19 in India (ECO-19)

Post Date: 
2020-07-09
   |   
Countries: 
India
   |   
Clinical Sites: 
BJGMC
This study was terminated May 25, 2021 This is a prospective cohort study of adults with suspected COVID-19 to address key knowledge gaps in the epidemiology of disease severity and poor clinical outcomes in India. Results from this study may help clinicians in India focus limited health resources...

Sex and gender differences in COVID testing, hospital admission, presentation, and drivers of severe outcomes in the DC/Maryland region

Post Date: 
2021-08-31
   |   
Countries: 
United States
Publication: 
medRxiv
Rates of severe illness and mortality from SARS-CoV-2 are greater for males, but the mechanisms for this difference are unclear.

A Case Study of Intra-Family Clustering of COVID-19 in India

Post Date: 
2021-08-18
   |   
Countries: 
India
Publication: 
European Journal of Pharmaceutical and Medical Research
Background: With unprecedented COVID-19 disease-related morbidity and mortality globally, understanding the transmission dynamics of this disease is of paramount importance for disease control efforts. Despite the lockdown in India, there has been reported an ever-increasing number of infected...

Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19

Post Date: 
2021-03-24
   |   
Countries: 
United States
Publication: 
JAMA Network Open
Just Published in JAMA Network Open: In this retrospective analysis, remdesivir was associated with faster clinical improvement of COVID-19 in a cohort of predominantly non-White patients

Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19

Post Date: 
2021-03-02
Publication: 
Annals of Internal Medicine
Dr. Matt Robinson and colleagues developed a real-time tool that can predict severe disease or death among COVID patients

Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis

Post Date: 
2020-12-28
   |   
Countries: 
United States
Publication: 
Open Forum Infectious Diseases
Background: There is currently no single treatment that mitigates all harms caused by severe acute respiratory syndrome coronavirus 2 infection. Tocilizumab, an interleukin-6 antagonist, may have a role as an adjunctive immune-modulating therapy. Methods: This was an observational retrospective...

The burden of anxiety among people living with HIV during the COVID-19 pandemic in Pune, India

Post Date: 
2020-10-23
   |   
Countries: 
India
Publication: 
BMC Public Health
Introduction: Globally, India has the third largest population of people living with HIV (PLHIV) and the second highest number of COVID-19 cases. Anxiety is associated with antiretroviral therapy (ART) nonadherence. It is crucial to understand the burden of anxiety and its sources among Asian...

Patient Trajectories Among Persons Hospitalized for COVID-19: A Cohort Study

Post Date: 
2020-09-22
   |   
Countries: 
United States
Publication: 
Annals of Internals Medicine
Risk factors for progression of coronavirus 2019 (COVID-19) to severe disease or death are underexplored in U.S. cohorts.

Mental health and quality of life among healthcare professionals during the COVID-19 pandemic in India

Post Date: 
2020-09-11
   |   
Countries: 
India
Publication: 
Brain and Behavior
Background: The COVID-19 pandemic has placed healthcare professionals (HCP) in stressful circumstances with increased patient loads and a high risk of exposure. We sought to assess the mental health and quality of life (QoL) of Indian HCPs, the fourth highest-burden country for COVID-19. Method:...

Pandemic Response

Post Date: 
2021-04-29
Bollinger R. Panelist. Pandemic Response. Maryland-National Capital Region Emergency Response System 2021 Virtual Symposium. Apri 28-29, 2021.

COVID-19 Lessons Learned

Post Date: 
2021-04-28
   |   
Clinical Sites: 
BJGMC
Bollinger R. Speaker. COVIS-19 Lessons Learned. 47th Annual Annual Conference of Research Society, BJGMC and Sassoon General Hospital. Virtual confernece, based in Pune, India. Apri 28-29, 2021.

Experts say COVID-19 mutations are normal

Post Date: 
2021-01-15
Dr. Robert Bollinger: “... As with any virus, changes are something to be watched, to ensure that testing and vaccines are still effective.